They found circulating CAR T cells to express higher TIGIT levels in non-responders, and could validate the relevance of this finding in an in-vivo model in which TIGIT blockade led to longer survival of mice challenged with lymphoma cells and CAR T cells. The gene discussed is TIGIT; the disease is lymphoma.